RESUMO
Mushrooms have been used as components of human diet and many ancient documents written in oriental countries have already described the medicinal properties of fungal species. Some mushrooms are known because of their nutritional and therapeutical properties and all over the world some species are known because of their toxicity that causes fatal accidents every year mainly due to misidentification. Many different substances belonging to poisonous mushrooms were already identified and are related with different symptoms and signs. Carcinogenicity, alterations in respiratory and cardiac rates, renal failure, rhabidomyolisis and other effects were observed in toxicity studies with various species including edible and therapeutic ones. Proper identification is important to avoid accidents and toxicity studies are necessary to assure the safe use of mushrooms as food and for medicinal purposes.
Assuntos
Agaricales/química , Intoxicação Alimentar por Cogumelos , Micotoxinas/análise , Micotoxinas/toxicidade , Adolescente , Adulto , Agaricales/classificação , Idoso , Animais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neurotoxinas/toxicidade , Adulto JovemRESUMO
INTRODUCTION: Metabolic, biochemical and enzymatic alterations are common in patients with cancer. Medicinal fungi has been used as adjuvants in cancer therapy due to its immunomodulatory and nutritional effects. OBJECTIVE: The objective of this study was to evaluate the metabolic and blood pressure effects on patients with colorectal cancer after dietary supplementation with Agaricus sylvaticus. METHODS: The methodology used was a randomized, double-blind, placebo-controlled clinical trial conducted at the Base Hospital of the Federal District-Brazil. Samples of 56 patients with colorectal cancer, divided into two groups: Agaricus sylvaticus (30 mg/kg/day) and placebo. Three serum evaluations were conducted throughout the treatment: glucose, total cholesterol, triglycerides, uric acid, urea, creatinine, alkaline phosphatase; total, direct and indirect bilirubin; aspartate aminotransferase and alanine aminotransferase; immunoglobulins A (IgA), G (IgG) and M (IgM); total proteins and protein fractions; blood pressure levels were measured as well. The results were analyzed by Microsoft Excel 2003 and SPSS 14.0 programs, Student's t test, F statistical test, with p < 0.05. RESULTS: The Agaricus sylvaticus group presented a significant reduction of fasting plasma glucose (p = 0.02), total cholesterol (p = 0.01), creatinine (p = 0.05), aspartate aminotransferase (p = 0.05), alanine aminotransferase (p = 0.04), IgA (p = 0.0001), IgM (p = 0.02), systolic blood pressure (p = 0.0001) and diastolic blood pressure (p = 0.0001). These alterations were not observed in the placebo group. CONCLUSIONS: Results suggest that dietary supplementation with Agaricus sylvaticus is capable of providing metabolic benefits to the biochemical, enzymatic and blood pressure parameters of patients with colorectal cancer in the postsurgical phase.
Assuntos
Agaricus/química , Pressão Sanguínea/efeitos dos fármacos , Neoplasias Colorretais/dietoterapia , Neoplasias Colorretais/metabolismo , Suplementos Nutricionais , Período Pós-Operatório , Adulto , Idoso , Brasil , Neoplasias Colorretais/cirurgia , Método Duplo-Cego , Feminino , Glucose/metabolismo , Humanos , Imunoglobulinas/análise , Estilo de Vida , Lipídeos/sangue , Testes de Função Hepática , Masculino , Pessoa de Meia-IdadeRESUMO
INTRODUCTION: Therapeutical alternatives, directed to improve life quality and reduce adverse effects of cancer treatment, have been the purpose of studies that try to prove the immunomodulator efficacy of medicinal fungi as coadjuvant for conventional therapies. OBJECTIVE: The objective of this study was to evaluate the impact on the life quality of post-surgical patients with colorectal cancer after supplemented diet with Agaricus sylvaticus fungus cultivated in Brazil. METHODS: Randomized, double-blind, placebo-controlled clinical trial carried out at the Federal District Base Hospital-Brazil, for six months. Samples of 56 enrolled patients (24 men and 32 women), stadium phases I, II and III, separated as placebo and Agaricus sylvaticus (30 mg/kg/day) supplemented groups. Form-standard and direct anamnesis-standard were used to evaluate indicators for life quality. The method of analysis was qualitative and descriptive, processed with Microsoft Excel 2003 and Epi Info 2004 programs. The protocol was approved by the Ethics Research Committee-Health Department-Federal District. RESULTS: After six months of treatment, the supplemented group had increased adhesion to physical activity; improved disposition and good mood; reduced complaints of pains and alterations of sleep such as insomnia and restless sleep; presenting more appetite, reduced constipation, diarrhea, alternate diarrhea/constipation, flatulence, flatus retention, pyrosis, postprandial fullness, nausea, abdominal distention and abdominal pain, facts not observed in the placebo group. CONCLUSIONS: The results suggest that a dietary supplement with Agaricus sylvaticus fungus is capable of improving the life quality of patients with colorectal cancer in post-surgical phase.